Voriconazole for Secondary Prophylaxis of Invasive Fungal Infections in Patients With Allogeneic Stem Cell Transplants (VOSIFI)
Prospective, Open-Label, Non-Comparative, Multicenter Study for the Secondary Prophylaxis of Invasive Fungal Infections (IFI) With Voriconazole in Patients With Allogeneic Stem Cell Transplants (SCT).
Sponsor: European Society for Blood and Marrow Transplantation
Listed as NCT00143312, this PHASE4 trial focuses on Prophylaxis Of Invasive Fungal Infections and remains completed. Sponsored by European Society for Blood and Marrow Transplantation, it has been updated 9 times since 2005, reflecting limited change activity. This study is part of the global effort to build evidence for infectious disease interventions.
Status Flow
Change History
9 versions recorded-
Jan 2026 — Present [monthly]
Completed PHASE4
-
Sep 2025 — Present [monthly]
Completed PHASE4
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Nov 2021 — Jul 2024 [monthly]
Completed PHASE4
▶ Show 4 earlier versions
-
Jan 2021 — Nov 2021 [monthly]
Completed PHASE4
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE4
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Feb 2005
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- European Society for Blood and Marrow Transplantation
- Pfizer
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Barcelona, Spain , Ch-4031 Basel, Switzerland , Cologne, Germany , Créteil, France , Leuven, Belgium , Lisbon, Portugal , London, United Kingdom , Madrid, Spain , Mainz, Germany , Manchester, United Kingdom and 6 more locations